Notification Letter to Registered H Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

Boan Biotech Authorizes Zencore Biologics to Use Its BA-HIEXcell® Stable Cell Line Development Platform

The platform can enhance the efficiency of biologics development by creating stable and highly expressed cell linesYantai, China, January 30, 2024 -- Boan Biotech (6955.HK) has entered into an agreeme...

Voluntary Announcement Authorization to Zencore Biologics to use BA-HIEXcell Stable Cell Line Development Platform

Boan Biotech Authorizes Joincare to Exclusively Develop and Commercialize Its BA2101 for Respiratory Indications in Chinese Mainland

Yantai, China, January 26, 2024 – Boan Biotech today announced a partnership with Joincare Pharmaceutical Group Industry Co., Ltd (Joincare). In this partnership, Joincare is granted the exclusi...

Voluntary Announcement Exclusive License Agreement for BA2101 in the Treatment of Respiratory System Diseases

2 CLDN 18.2-Targeted Drugs Granted ODD for Gastric Cancer in US

Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of gastric cancer (including cancer of gas...

Voluntary Announcement both BA1105 and BA1301 being Granted Orphan Drug Designations for Treatment of Gastric Cancer by FDA

Boan Biotech Obtains ANVISA GMP Certification

Boan Biotech announced today that it has received GMP certification from the Brazilian Agência Nacional de Vigilância Sanitária (ANVISA) for its biological product, Boyuno® (Bevaciz...

Voluntary Announcement the Company has Obtained GMP Certification for Boyuno from the Brazilian Agencia Nacional de Vigilancia Sanitaria